JP2015505371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505371A5 JP2015505371A5 JP2014552496A JP2014552496A JP2015505371A5 JP 2015505371 A5 JP2015505371 A5 JP 2015505371A5 JP 2014552496 A JP2014552496 A JP 2014552496A JP 2014552496 A JP2014552496 A JP 2014552496A JP 2015505371 A5 JP2015505371 A5 JP 2015505371A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- core protein
- virus core
- amino acid
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700721 Hepatitis B virus Species 0.000 claims 25
- 108010015780 Viral Core Proteins Proteins 0.000 claims 23
- 208000002672 hepatitis B Diseases 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 8
- 229940039227 diagnostic agent Drugs 0.000 claims 8
- 239000000032 diagnostic agent Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 239000007790 solid phase Substances 0.000 claims 7
- 102000014150 Interferons Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000011002 quantification Methods 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 206010061818 Disease progression Diseases 0.000 claims 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 3
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 3
- 230000005750 disease progression Effects 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 101710142246 External core antigen Proteins 0.000 claims 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 238000004364 calculation method Methods 0.000 claims 1
- 238000011088 calibration curve Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001917 fluorescence detection Methods 0.000 claims 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000005745 host immune response Effects 0.000 claims 1
- 238000003317 immunochromatography Methods 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000012417 linear regression Methods 0.000 claims 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210019389.5A CN103217533B (zh) | 2012-01-21 | 2012-01-21 | Anti-HBc定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途 |
| CN201210019389.5 | 2012-01-21 | ||
| PCT/CN2013/070573 WO2013107355A1 (zh) | 2012-01-21 | 2013-01-17 | Anti-hbc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017188500A Division JP2018036268A (ja) | 2012-01-21 | 2017-09-28 | 抗ＨＢｃ定量的検出方法、並びに慢性Ｂ型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505371A JP2015505371A (ja) | 2015-02-19 |
| JP2015505371A5 true JP2015505371A5 (enExample) | 2015-09-24 |
| JP6283319B2 JP6283319B2 (ja) | 2018-02-21 |
Family
ID=48798632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552496A Active JP6283319B2 (ja) | 2012-01-21 | 2013-01-17 | 抗ＨＢｃ定量的検出方法、並びに慢性Ｂ型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用 |
| JP2017188500A Abandoned JP2018036268A (ja) | 2012-01-21 | 2017-09-28 | 抗ＨＢｃ定量的検出方法、並びに慢性Ｂ型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017188500A Abandoned JP2018036268A (ja) | 2012-01-21 | 2017-09-28 | 抗ＨＢｃ定量的検出方法、並びに慢性Ｂ型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9952217B2 (enExample) |
| EP (1) | EP2805729B1 (enExample) |
| JP (2) | JP6283319B2 (enExample) |
| KR (1) | KR101739953B1 (enExample) |
| CN (1) | CN103217533B (enExample) |
| AU (2) | AU2013211346B2 (enExample) |
| BR (1) | BR112014017877B1 (enExample) |
| CA (1) | CA2861917C (enExample) |
| ES (1) | ES2714274T3 (enExample) |
| WO (1) | WO2013107355A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104338132A (zh) * | 2013-07-26 | 2015-02-11 | 复旦大学 | 一种病毒免疫治疗药物复合物及其用途 |
| CN106153923B (zh) * | 2016-06-21 | 2017-12-05 | 北京大学第一医院 | 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统 |
| CN107044977A (zh) * | 2016-06-30 | 2017-08-15 | 深圳市亚辉龙生物科技股份有限公司 | 一种酪氨酸磷酸酶抗体化学发光免疫检测试剂盒及其制备方法 |
| CN109991411B (zh) * | 2017-12-29 | 2023-01-20 | 上海索昕生物科技有限公司 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
| CN109900896A (zh) * | 2019-03-12 | 2019-06-18 | 江苏伯纳德生物科技发展有限公司 | 一种酶联免疫法检测试剂盒及其制备方法 |
| WO2022252745A1 (zh) * | 2021-06-02 | 2022-12-08 | 重庆医科大学 | 一种免疫分子病毒颗粒检测试剂盒 |
| CN117538520B (zh) * | 2024-01-05 | 2024-04-02 | 山东康华生物医疗科技股份有限公司 | 一种HBc-IgM抗体检测试剂盒及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0382962A (ja) * | 1989-08-28 | 1991-04-08 | Tosoh Corp | Ｂ型肝炎ウィルスＣｏｒｅ抗原に対する抗体の検出方法 |
| JP4292670B2 (ja) * | 2000-02-08 | 2009-07-08 | 東ソー株式会社 | 抗ＨＢｃ抗体の免疫測定法 |
| EP1535927B1 (en) | 2002-09-06 | 2010-07-14 | Advanced Life Science Institute, Inc. | Hbv precore protein capable of forming particles |
| CN1908666B (zh) * | 2006-08-14 | 2010-05-12 | 武汉大学 | 一种检测乙肝核心抗体的双夹心法酶联免疫诊断试剂盒及应用 |
| CN101545906A (zh) * | 2008-03-25 | 2009-09-30 | 北京科美东雅生物技术有限公司 | 乙肝核心抗体磁微粒化学发光免疫分析测定试剂盒及其制备方法 |
| CN101377496A (zh) * | 2008-04-16 | 2009-03-04 | 北京科美东雅生物技术有限公司 | 一种检测甲状腺过氧化物酶自身抗体的化学发光免疫分析测定试剂盒 |
| CN101726596A (zh) * | 2009-11-04 | 2010-06-09 | 无锡中德伯尔生物技术有限公司 | 检测乙肝五项的荧光微球免疫层析检测卡及其制备方法 |
-
2012
- 2012-01-21 CN CN201210019389.5A patent/CN103217533B/zh active Active
-
2013
- 2013-01-17 CA CA2861917A patent/CA2861917C/en active Active
- 2013-01-17 JP JP2014552496A patent/JP6283319B2/ja active Active
- 2013-01-17 WO PCT/CN2013/070573 patent/WO2013107355A1/zh not_active Ceased
- 2013-01-17 EP EP13738450.9A patent/EP2805729B1/en active Active
- 2013-01-17 ES ES13738450T patent/ES2714274T3/es active Active
- 2013-01-17 US US14/373,611 patent/US9952217B2/en active Active
- 2013-01-17 AU AU2013211346A patent/AU2013211346B2/en active Active
- 2013-01-17 BR BR112014017877-1A patent/BR112014017877B1/pt active IP Right Grant
- 2013-01-17 KR KR1020147023123A patent/KR101739953B1/ko active Active
-
2017
- 2017-09-28 JP JP2017188500A patent/JP2018036268A/ja not_active Abandoned
-
2018
- 2018-01-31 AU AU2018200744A patent/AU2018200744B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen | |
| JP2015505371A5 (enExample) | ||
| Gani et al. | An automated, quantitative, and multiplexed assay suitable for point-of-care hepatitis B virus diagnostics | |
| Yildiz et al. | Recent advances in micro/nanotechnologies for global control of hepatitis B infection | |
| JP2012509477A5 (enExample) | ||
| JP2019027952A (ja) | リン酸化タウタンパク質の測定方法 | |
| Matsumoto et al. | Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody | |
| US20150192583A1 (en) | Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients | |
| JP2018036268A (ja) | 抗ＨＢｃ定量的検出方法、並びに慢性Ｂ型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用 | |
| JP2015508892A5 (enExample) | ||
| Thibault et al. | Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples | |
| van Halewijn et al. | Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients | |
| Xiang et al. | A simple and rapid capillary chemiluminescence immunoassay for quantitatively detecting human serum HBsAg | |
| Jabłonowska et al. | Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir | |
| Kaysheva et al. | Mass spectrometric detection of the amino acid sequence polymorphism of the hepatitis C virus antigen | |
| JP5648905B2 (ja) | 肝臓がん発症の検出又はリスクの予測方法 | |
| Xu et al. | Comparison of two immunoassays for determining hepatitis B virus serum markers | |
| Schobesberger et al. | Microfluidic Immunoassay for the Detection of SARS-CoV-2 Neutralizing Antibodies in Ultralow-Volume Human Plasma Samples | |
| CN106596939B (zh) | 用于肝癌体外诊断试剂盒及其检测方法 | |
| Inoue et al. | Current global applications of HBcrAg assays in the management of chronic hepatitis B | |
| Lee et al. | Evaluation of two SARS-CoV-2 IgG/IgM Rapid Tests in Capillary Blood Samples. | |
| CN106153923B (zh) | 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统 | |
| JP7622350B2 (ja) | 高感度な抗ｈｂｖ抗体の検出方法 | |
| Wang et al. | Specific chemokines CCL2 and CCL17 are correlated with hepatic necro-inflammation in chronic hepatitis B patients with normal/mildly elevated alanine aminotransaminase levels | |
| Liu et al. | Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies |